By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.


September 2, 2003


Founder: Charles Homcy and David Philips

CEO: William Lis

CFO: Mardi Dier

CTO: R. Andrew Ramelmeier


Please click here for Portola job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA

Start Up

Company News
Portola (PTLA) Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting 9/13/2016 8:12:48 AM
Portola (PTLA) Announces Interim Results From Ongoing Phase IIIb/IV ANNEXXA-4 Study Of Factor Xa Inhibitor Antidote Andexxa (Andexanet Alfa) In Patients With Acute Major Bleeding 8/30/2016 8:10:05 AM
Portola (PTLA) Announces Presentation Of Interim Results From Phase IIIb/IV ANNEXA-4 Study Of Andexxa (Andexanet Alfa) At European Society of Cardiology 2016 Congress 8/26/2016 8:00:01 AM
Portola (PTLA) Announces Validation Of Marketing Authorization Application (MAA) By EMA For Indexxa (Andexanet Alfa), A Factor Xa Inhibitor Antidote 8/19/2016 6:56:45 AM
Bay Area's Portola (PTLA) Plummets as FDA Rejects AndexXa NDA 8/18/2016 5:43:58 AM
Portola (PTLA) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/10/2016 11:09:20 AM
Portola (PTLA) To Announce Second Quarter 2016 Financial Results And Host Conference Call On Tuesday, August 9 8/3/2016 10:56:59 AM
10 Biotech Stocks that Could Blow Up in Q3 7/6/2016 6:56:11 AM
5 Biotech Stocks at Bargain Basement Prices 6/21/2016 7:42:08 AM
Portola (PTLA) Announces Full Results Of Phase 3 APEX Study Of Betrixaban Presented At International Society On Thrombosis And Haemostasis (ISTH) Meeting 5/27/2016 9:37:43 AM